Australia markets closed

Skye Bioscience, Inc. (SKYE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.02+0.03 (+0.23%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 364.54M
Enterprise value 367.90M
Trailing P/E 0.82
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)87.34
Enterprise value/revenue N/A
Enterprise value/EBITDA -10.05

Trading information

Stock price history

Beta (5Y monthly) 1.71
52-week change 3224.75%
S&P500 52-week change 322.43%
52-week high 319.41
52-week low 31.44
50-day moving average 313.15
200-day moving average 35.82

Share statistics

Avg vol (3-month) 346.46k
Avg vol (10-day) 378.77k
Shares outstanding 528.06M
Implied shares outstanding 628.06M
Float 811.67M
% held by insiders 17.08%
% held by institutions 157.67%
Shares short (15 Apr 2024) 446.74k
Short ratio (15 Apr 2024) 41.95
Short % of float (15 Apr 2024) 40.27%
Short % of shares outstanding (15 Apr 2024) 40.17%
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:250
Last split date 308 Sept 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-80.28%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -13.4M
Net income avi to common (ttm)-37.64M
Diluted EPS (ttm)-5.37
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.38M
Total cash per share (mrq)0.05
Total debt (mrq)4.62M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.84
Book value per share (mrq)-0.17

Cash flow statement

Operating cash flow (ttm)-13.95M
Levered free cash flow (ttm)-10.91M